2 Under-the-Radar Stocks to Buy and Hold

Axsome reported 2025 revenue up 66% to $638.5M and narrowed net loss per share to $3.68 from $5.99 in 2024; its late-stage pipeline, including an Auvelity AD-agitation filing with analyst peak-sales estimates of $1.5–3.0B (company projects >$16B peak across assets), underpins upside to profitability. Madrigal's FDA approval of Rezdiffra drove revenue to $958.4M in 2025 from $180.1M in 2024, with ~36,250 patients treated (≈17% of a 315,000 specialist-patient target); product is on accelerated approval pending confirmatory trials, a key regulatory risk to monitor. Overall outlook is positive for both names and likely supportive of stock-level upside, but confirmatory trial/regulatory risk for Madrigal is a material caveat.

Analysis

AXSM and MDGL sit on asymmetric clinical-commercial optionality that the market is pricing as a binary lottery rather than a staged investment. For AXSM, the most important second-order effect is how a successful late‑stage readout would alter negotiating leverage with specialty pharmacies and PBMs — enabling higher realized net price and faster formulary access, but also inviting immediate competitive response from larger CNS platforms that can subsidize access. For MDGL, early prescribing momentum is a double‑edged sword: concentrated uptake among specialists de‑risks launch economics but raises sensitivity to utilization management and diagnostics adoption rates that determine addressable reach over the next 24 months.

Key catalysts cluster in predictable windows: trial readouts and label/label‑extension decisions in the next 6–24 months will drive >50% of near‑term value volatility. Tail risks that could erase current optionality include a negative safety signal (rapid share decline within days), adverse payer rulings or step‑edit rollouts (materially slowing quarterly growth), and manufacturing/API interruptions that push COGS higher and margin guidance down. A successful outcome will not be linear: expect several 20–40% intraday moves tied to prescriber guidance, coverage decisions, and headline readouts rather than steady re‑rating.

From a positioning standpoint, the market appears to be extrapolating peak penetration too early; the real value is in sequential readout de‑risking and demonstrable durable coverage. Tactical structures that capture upside from discrete catalysts while capping downside are preferable to naked equity exposure; funding those structures with short‑dated, volatility‑rich hedges (puts or tight call spreads) materially improves asymmetric R/R. Maintain active monitoring of specialty distribution agreements and PBM tiering language — changes there are often leading indicators of durable commercial outcomes.

Key Decisions for Investors

• AXSM — Buy a 12–18 month call‑spread (long 12‑18m ATM call / short ~30–40% OTM call) sized to 1–2% notional of biotech book. Rationale: captures upside from upcoming late‑stage readouts and potential label expansions while capping premium decay. Risk/Reward: asymmetric ≈ +60–100% if readouts and favorable formulary headlines, limited loss = premium paid (~100%).
• MDGL — Accumulate core long position sized to 2–3% of portfolio while buying 9–12 month protective puts (approx. 10–15% OTM) to limit downside from confirmatory/regulatory reversal or abrupt utilization management. Rationale: preserves capture of ongoing commercial momentum but hedges the accelerated‑approval pathway risk. Risk/Reward: upside >2x if continued adoption and broadened coverage; downside capped to put strike premium reduction.
• Pair idea — Long MDGL / Short AXSM (equal notional) over 6–12 months for event arbitrage: long exposure to durable uptake story, short exposure to binary late‑stage readout risk. Rationale: isolates commercial vs. clinical binary risk. Risk/Reward: profitable if MDGL commercial momentum outpaces AXSM’s event‑driven volatility; hedge size to neutralize market beta.
• Trigger & monitoring rules: scale into positions ahead of primary readouts (start 2–6 weeks prior), increase hedges immediately on any adverse safety/coverage headlines, and take 30–50% profits if implied probability of success (based on option markets) rises >20 percentage points pre‑event.